EyePoint Pharmaceuticals adds a fresh Street voice this week, but the options market and a sticky short base tell a more cautious story ahead of its July 31 earnings event.
The newest development is Cantor Fitzgerald's initiation on July 8, with analyst Steve Seedhouse assuming coverage at Overweight and a $47 price target. That adds a tenth buy-side voice to an already heavily bullish consensus. The picture from the broader analyst community is striking: the mean price target sits at roughly $40 against a $14.02 stock price — almost three times the current level. Chardan Capital's dramatic July 1 move from $29 to $65 remains the most aggressive call on record, while Guggenheim's reiterated $68 target sits even higher. RBC Capital is the outlier, holding at $37 after a small trim in May. Every analyst with an active view is broadly constructive; the disagreement is only on degree.
Options traders are not sharing that conviction. The put/call ratio has climbed to 1.86, well above its 20-day average of 1.39 and roughly 1.7 standard deviations above the mean — near the highest defensive reading of the past year, with the 52-week peak at 2.20. The shift is visible in the history: the PCR ran in a tight band around 1.05 through most of May and early June, then jumped sharply in late June and has stayed elevated through this week. With earnings three weeks out, options traders are paying meaningfully more for downside protection relative to upside exposure than they have at almost any point over the past year.
Short interest reinforces that the market is not yet buying the analyst thesis. Short interest holds at 18.7% of the free float — nearly unchanged on the week, up roughly 7% over the past month. That is a large short base for a Nasdaq pharma name, and it has been remarkably stable even as Chardan's dramatic upgrade landed last week. The borrow market itself remains loose: availability is running at roughly 559% of outstanding short interest, and cost to borrow is just 0.63% annualised — even after a 26% rise over the past week. Shorts face no near-term squeeze mechanics. The ORTEX short score sits at 68, edged down fractionally from 69 earlier in the week but still elevated.
Institutional ownership provides useful context on the divide. The top holders are dominated by specialist biotech funds — Suvretta and Cormorant each hold close to 10% of shares. Commodore Capital entered with a full 4.25 million share position as recently as May. BlackRock added 600,000 shares in the period to June 30. These are not passive drifters; the institutional base is actively building. Yet even that buying has not dislodged the short interest from its range. Among correlated peers this week, TARS gained 15% and TLPH added 13%, while EYPT fell 2%. The peer divergence suggests the weakness is stock-specific rather than sector-driven.
With earnings on July 31, the tension between a deeply bullish analyst community, specialist institutional accumulation, and a stubborn 18%-plus short base that has barely moved on multiple positive catalysts is the defining characteristic of EYPT right now — and whether the options market's elevated defensiveness proves well-founded or premature will likely hinge on whatever DURAVYU clinical or regulatory news accompanies that next print.
See the live data behind this article on ORTEX.
Open EYPT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
